Abbott Labs, AstraZeneca to co-promote Trilipix

ABBOTT PARK, Ill. Two drug companies have extended a relationship to include co-promotion of a drug used to treat certain lipid disorders.

Abbott Labs and AstraZeneca announced Thursday that they would co-promote Trilipix (fenofibric acid) in the United States, though not in Puerto Rico.

“Abbott’s portfolio of lipid therapies is designed to help physicians manage a patient’s total lipid profile,” Abbott divisional VP primary care Jeffrey Stewart said. “With AstraZeneca’s established presence in the cardiovascular space, this agreement allows Abbott to expand visibility and education of Trilipix among physicians whose patients may benefit from this medication.”

The drug is designed to be used alone or with a statin to lower triglycerides and “bad” LDL cholesterol while increasing “good” HDL cholesterol.